- Class: Peptide receptor radionuclide therapy (PRRT).
- Type: Radiolabeled somatostatin analog.
Mechanism of Action (MOA)
- DOTATATE is a somatostatin analog that binds somatostatin receptor subtype 2 (SSTR2), overexpressed on neuroendocrine tumor (NET) cells.
- Conjugated to Lutetium-177, a beta-emitting radionuclide.
- Delivers targeted radiation → DNA damage and tumor cell death (“cross-fire” effect kills nearby cells).
Clinical Uses
- Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs):
- Advanced, unresectable, or metastatic tumors.
- Typically after progression on somatostatin analog therapy (octreotide or lanreotide).
Dosing (Adults)
- 7.4 GBq (200 mCi) IV infusion every 8 weeks, for 4 cycles.
- Infuse over ~30–40 minutes.
- Co-administer amino acid solution (lysine/arginine) to protect kidneys from radiation nephrotoxicity.
Toxicities
- Hematologic: anemia, thrombocytopenia, neutropenia – usually transient.
- Renal toxicity – mitigated by amino acid infusion.
- Nausea/vomiting – often due to amino acid infusion.
- Fatigue.
- Rare: hepatotoxicity, secondary myelodysplastic syndrome (MDS) or leukemia.
- Hypersensitivity reactions – uncommon.
Monitoring
- CBC prior to each cycle.
- Renal function (creatinine, GFR) before and during therapy.
- Liver function tests.
- Monitor for nausea during amino acid infusion.
- Follow radiation safety protocols for handling patient excreta.
Summary
Lutetium-177 DOTATATE (Lutathera®) is a PRRT agent for somatostatin receptor-positive GEP-NETs. Key concerns are hematologic toxicity, renal protection, nausea management, and radiation safety, requiring amino acid co-infusion and careful monitoring of blood counts and renal function.